SEP 10, 2014 10:00 AM PDT

NGS Lessons in Translational Diagnostics

SPONSORED BY: Asuragen, Asuragen
48 37 4398

  • Gary Latham Ph.D., Vice President, Research & Technology Development, AsuragenBrian Haynes, Ph.D., Senior Scientist, Computational Biology, Asuragen
      Dr. Gary Latham PhD is a founding member of Asuragen, having joined the company in March of 2006.  He leads assay development and sample prep technology activities for the Research division and the Genomics Services group, and oversees the company's Bioinformatics team.  His accomplishments include the conception and development of Asuragen's AmplideX® PCR technology for fragile X syndrome and autism, and multiple innovations in next-generation sequencing that are commercialized under the SuraSeq® brand.  Dr. Latham is an author on >30 peer-reviewed publications, and an inventor on 9 issued and more than a dozen pending US and international patents. Dr. Latham received his Ph.D. degree in Biochemistry from Vanderbilt University, and was an American Cancer Society Postdoctoral Fellow at the University of Oregon's Institute for Molecular Biology.

      Dr. Brian Haynes received his Ph.D. degree from the Department of Computer Science at Washington University in St. Louis.  His doctoral work focused on the integration of RNA-Seq and ChIP-Seq technologies to model transcriptional networks that regulate carcinogenesis and microbial pathogenesis.  Brian joined Asuragen in November of 2012 as a Senior Scientist in the Computational Biology group.  Since joining Asuragen, he has spearheaded the initiative to adopt whole transcriptome (WT) RNA-Seq as a tool for broad unbiased biomarker discovery.  He has applied WT RNA-Seq to discover novel diagnostic markers in thyroid cancer and identify patient response stratification signatures in late phase drug trials.  Brian has also led the research and development effort of translating these discoveries into a clinical assay format with targeted RNA-Seq.


    In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low-quantity (FFPE or FNA) tumor biopsies.  We will also discuss how these markers can be queried using a unified assay approach that reveals cancer-associated DNA and RNA variants from total nucleic acid.  Finally, we will share lessons learned from building high-performance, multi-modal cancer panels that incorporate functional nucleic acid quantification, highly multiplexed target enrichment, and versatile and complementary variant call pipelines. These methods can enable reliable detection and quantification of DNA mutations, expression markers, and RNA fusions across multiple disease pathways and cancer types to advance diagnostic, theranostic and prognostic applications, and support retrospective studies, clinical trial assays, and in vitro diagnostic products.


    Objectives of webinar:

    • Explain the relationship between functional DNA and RNA (QFI) from FFPE and FNA biopsies and NGS data interpretation
    • Analyze the opportunities and challenges of mRNA and fusion biomarker discovery from RNA-Seq of FFPE and FNA specimens
    • Describe the migration of expression and fusion biomarkers from whole transcriptome RNA-Seq to targeted RNA-Seq
    • Summarize the benefits of a tandem DNA/RNA NGS cancer panel and integrated workflow for clinical oncology and drug development


    Show Resources
    Loading Comments...